Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Feasibility Phase I Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT06066138
Title field or adapter rule
{'original_value': 'A Feasibility Phase I Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At
2026-10-31T23:27:36.718162+00:00
Published At
2026-10-16T00:00:00+00:00
Record Updated At
2026-10-16
Source Retrieved At
2026-10-31T22:19:02.163121+00:00
Timestamp Basis
ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation
ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Locally Advanced Alveolar Soft Part Sarcoma", "Metastatic Alveolar Soft Part Sarcoma", "Locally Advanced Non Small Cell Lung Cancer", "Metastatic Non Small Cell Lung Cancer", "Locally Advanced Small Cell Lung Cancer", "Metastatic Small Cell Lung Cancer", "Locally Advanced Hepatocellular Carcinoma", "Metastatic Hepatocellular Carcinoma", "Locally Advanced Melanoma", "Metastatic Melanoma"]
protocolSection.statusModule.lastUpdatePostDateStruct
{"date": "2026-10-16", "type": "ACTUAL"}
protocolSection.identificationModule.nctId
"NCT06066138"
protocolSection.identificationModule.officialTitle
"A Feasibility Phase I Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct
null

Study condition terms

  • Locally Advanced Alveolar Soft Part Sarcoma (protocolSection.conditionsModule.conditions)
  • Metastatic Alveolar Soft Part Sarcoma (protocolSection.conditionsModule.conditions)
  • Locally Advanced Non Small Cell Lung Cancer (protocolSection.conditionsModule.conditions)
  • Metastatic Non Small Cell Lung Cancer (protocolSection.conditionsModule.conditions)
  • Locally Advanced Small Cell Lung Cancer (protocolSection.conditionsModule.conditions)
  • Metastatic Small Cell Lung Cancer (protocolSection.conditionsModule.conditions)
  • Locally Advanced Hepatocellular Carcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Hepatocellular Carcinoma (protocolSection.conditionsModule.conditions)
  • Locally Advanced Melanoma (protocolSection.conditionsModule.conditions)
  • Metastatic Melanoma (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

  • {'armGroupLabels': ['Arm 1'], 'description': 'Atezolizumab administered via IV at either 1,200 mg q3 weeks, or 1,680 mg q4 weeks for the first 2 doses followed by 840mg q2 weeks or q6 weeks.', 'name': 'Atezolizumab', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

  • Atezolizumab (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.